ResMed Inc. (NYSE:RMD) Stock Holdings Reduced by Orion Capital Management LLC

Orion Capital Management LLC lowered its position in ResMed Inc. (NYSE:RMD) by 5.8% during the fourth quarter, HoldingsChannel.com reports. The firm owned 3,555 shares of the medical equipment provider’s stock after selling 220 shares during the quarter. Orion Capital Management LLC’s holdings in ResMed were worth $612,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the company. EverSource Wealth Advisors LLC lifted its position in shares of ResMed by 224.6% in the third quarter. EverSource Wealth Advisors LLC now owns 185 shares of the medical equipment provider’s stock worth $27,000 after buying an additional 128 shares during the last quarter. Operose Advisors LLC acquired a new stake in shares of ResMed in the third quarter worth about $32,000. Planned Solutions Inc. acquired a new stake in shares of ResMed in the fourth quarter worth about $34,000. MV Capital Management Inc. lifted its position in shares of ResMed by 39.0% in the fourth quarter. MV Capital Management Inc. now owns 214 shares of the medical equipment provider’s stock worth $37,000 after buying an additional 60 shares during the last quarter. Finally, Turtle Creek Wealth Advisors LLC acquired a new stake in shares of ResMed in the fourth quarter worth about $45,000. Hedge funds and other institutional investors own 54.98% of the company’s stock.

Analyst Upgrades and Downgrades

RMD has been the subject of a number of analyst reports. Needham & Company LLC boosted their price target on ResMed from $224.00 to $236.00 and gave the stock a “buy” rating in a research report on Friday, April 26th. KeyCorp boosted their price target on ResMed from $227.00 to $238.00 and gave the stock an “overweight” rating in a research report on Friday, April 26th. Mizuho reissued a “buy” rating and set a $215.00 price objective on shares of ResMed in a research report on Wednesday, March 27th. Royal Bank of Canada boosted their price objective on ResMed from $187.00 to $200.00 and gave the stock a “sector perform” rating in a research report on Friday, April 26th. Finally, Oppenheimer cut their price objective on ResMed from $205.00 to $200.00 and set an “outperform” rating for the company in a research report on Friday, April 26th. Four analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $202.80.

Insider Activity

In other news, Director Peter C. Farrell sold 10,935 shares of the company’s stock in a transaction that occurred on Thursday, February 22nd. The stock was sold at an average price of $182.66, for a total value of $1,997,387.10. Following the sale, the director now directly owns 157,404 shares in the company, valued at approximately $28,751,414.64. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In related news, Director Peter C. Farrell sold 10,935 shares of the stock in a transaction that occurred on Thursday, February 22nd. The stock was sold at an average price of $182.66, for a total transaction of $1,997,387.10. Following the sale, the director now directly owns 157,404 shares in the company, valued at approximately $28,751,414.64. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, General Counsel Michael J. Rider sold 200 shares of the stock in a transaction that occurred on Friday, March 1st. The stock was sold at an average price of $173.25, for a total value of $34,650.00. Following the sale, the general counsel now owns 6,688 shares in the company, valued at $1,158,696. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 11,641 shares of company stock worth $2,137,958. Company insiders own 1.21% of the company’s stock.

ResMed Stock Performance

ResMed stock traded up $2.16 during trading hours on Wednesday, hitting $216.15. The stock had a trading volume of 777,694 shares, compared to its average volume of 1,072,425. The company has a 50-day moving average of $188.47 and a two-hundred day moving average of $173.40. The company has a quick ratio of 1.97, a current ratio of 3.04 and a debt-to-equity ratio of 0.22. The company has a market cap of $31.75 billion, a PE ratio of 32.98, a price-to-earnings-growth ratio of 2.70 and a beta of 0.67. ResMed Inc. has a fifty-two week low of $132.24 and a fifty-two week high of $240.09.

ResMed (NYSE:RMD) last posted its quarterly earnings results on Thursday, April 25th. The medical equipment provider reported $2.13 EPS for the quarter, beating the consensus estimate of $1.91 by $0.22. ResMed had a return on equity of 24.43% and a net margin of 20.91%. The firm had revenue of $1.20 billion during the quarter, compared to analysts’ expectations of $1.17 billion. During the same quarter in the prior year, the firm posted $1.68 EPS. The company’s revenue for the quarter was up 7.2% on a year-over-year basis. On average, equities research analysts anticipate that ResMed Inc. will post 7.55 EPS for the current fiscal year.

ResMed Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, June 13th. Stockholders of record on Thursday, May 9th will be paid a $0.48 dividend. The ex-dividend date is Wednesday, May 8th. This represents a $1.92 annualized dividend and a dividend yield of 0.89%. ResMed’s dividend payout ratio is currently 29.49%.

ResMed Company Profile

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. It operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes.